Evaluation of the Efficacy and Safety of Topical Imiquimod 5% for Plaque-Type Morphea: A Multicenter, Prospective, Vehicle-Controlled Trial
Authors:
- 11 March 2015
- journal article
- research article
- Published by SAGE Publications in Journal of Cutaneous Medicine and Surgery
- Vol. 19 (2) , 132-139
Abstract
Background: There is currently a lack of evidence-based therapies that are safe and effective for plaque-type morphea. We aimed to evaluate the therapeutic potential and safety profile of imiquimod 5% cream in plaque-type morphea. Methods: We enrolled 25 adult patients from two Canadian centers with histologically confirmed plaque-type morphea. Imiquimod 5% was applied to a representative plaque, and vehicle was applied to a control plaque for 9 months. Treatment efficacy was assessed with the Dyspigmentation, Induration, Erythema, and Telangiectasias (DIET) score, histology, and ultrasound evaluation. Results and Conclusions: Twenty-two patients completed the entire length of the study. Imiquimod 5% was superior to vehicle in reducing DIET scores at 3, 6, 9, and 12 months ( p < .05). Induration demonstrated the greatest response. Histologic evaluation showed significant improvement or resolution of disease. However, no ultrasonographic differences were found in dermal and hypodermal thicknesses between the treatment and vehicle groups ( p > .05). Adverse effects were minimal and well tolerated.Keywords
This publication has 21 references indexed in Scilit:
- Morphea: Evidence-based recommendations for treatmentIndian Journal of Dermatology, Venereology and Leprology, 2012
- A systematic review of morphea treatments and therapeutic algorithmJournal of the American Academy of Dermatology, 2011
- Update on morpheaJournal of the American Academy of Dermatology, 2011
- IL-33 Induces IL-13–Dependent Cutaneous FibrosisThe Journal of Immunology, 2009
- First case series on the use of imiquimod for morphoeaBritish Journal of Dermatology, 2005
- Lack of Skin Fibrosis in Tight Skin (TSK) Mice with Targeted Mutation in the Interleukin-4Rα and Transforming Growth Factor-β GenesJournal of Investigative Dermatology, 2001
- Anti-IL-4 treatment prevents dermal collagen deposition in the tight-skin mouse model of sclerodermaEuropean Journal of Immunology, 1998
- Double-blind, placebo-controlled study of intralesional interferon gamma for the treatment of localized sclerodermaJournal of the American Academy of Dermatology, 1997
- Expression of Interleukin-4 in Scleroderma Skin Specimens and Scleroderma Fibroblast CulturesArchives of Dermatology, 1996
- IL-4-induced immune deviation as antigen-specific therapy for inflammatory autoimmune diseaseImmunology Today, 1996